Department of Oncology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Institutional Key Laboratory of Vascular Biology and Translational Medicine in Hunan Province, Hunan University of Chinese Medicine, Changsha, China.
J Cell Mol Med. 2024 May;28(9):e18353. doi: 10.1111/jcmm.18353.
Non-small-cell lung cancer (NSCLC) is a major cause of worldwide cancer death, posing a challenge for effective treatment. Our previous findings showed that Chinese herbal medicine (CHM) QiDongNing (QDN) could upregulate the expression of p53 and trigger cell apoptosis in NSCLC. Here, our objective was to investigate the mechanisms of QDN-induced apoptosis enhancement. We chose A549 and NCI-H460 cells for validation in vitro, and LLC cells were applied to form a subcutaneous transplantation tumour model for validation in more depth. Our findings indicated that QDN inhibited multiple biological behaviours, including cell proliferation, cloning, migration, invasion and induction of apoptosis. We further discovered that QDN increased the pro-apoptotic BAX while inhibiting the anti-apoptotic Bcl2. QDN therapy led to a decline in adenosine triphosphate (ATP) and a rise in reactive oxygen species (ROS). Furthermore, QDN elevated the levels of the tumour suppressor p53 and the mitochondrial division factor DRP1 and FIS1, and decreased the mitochondrial fusion molecules MFN1, MFN2, and OPA1. The results were further verified by rescue experiments, the p53 inhibitor Pifithrin-α and the mitochondrial division inhibitor Mdivi1 partially inhibited QDN-induced apoptosis and mitochondrial dysfunction, whereas overexpression of p53 rather increased the efficacy of the therapy. Additionally, QDN inhibited tumour growth with acceptable safety in vivo. In conclusion, QDN induced apoptosis via triggering p53/DRP1-mediated mitochondrial fission in NSCLC cells.
非小细胞肺癌(NSCLC)是全球癌症死亡的主要原因,对有效治疗构成挑战。我们之前的研究结果表明,中药(CHM)芪冬宁(QDN)可以上调 p53 的表达并触发 NSCLC 细胞凋亡。在这里,我们的目的是研究 QDN 诱导细胞凋亡增强的机制。我们选择 A549 和 NCI-H460 细胞进行体外验证,并用 LLC 细胞形成皮下移植瘤模型进行更深入的验证。我们的研究结果表明,QDN 抑制了多种生物学行为,包括细胞增殖、克隆、迁移、侵袭和诱导凋亡。我们进一步发现,QDN 增加了促凋亡的 BAX,同时抑制了抗凋亡的 Bcl2。QDN 治疗导致三磷酸腺苷(ATP)水平下降和活性氧(ROS)水平升高。此外,QDN 上调了肿瘤抑制因子 p53 和线粒体分裂因子 DRP1 和 FIS1 的水平,降低了线粒体融合分子 MFN1、MFN2 和 OPA1 的水平。通过挽救实验进一步验证了这些结果,p53 抑制剂 Pifithrin-α和线粒体分裂抑制剂 Mdivi1 部分抑制了 QDN 诱导的细胞凋亡和线粒体功能障碍,而 p53 的过表达则增强了治疗效果。此外,QDN 在体内抑制肿瘤生长的同时具有可接受的安全性。总之,QDN 通过触发 p53/DRP1 介导的 NSCLC 细胞线粒体分裂诱导细胞凋亡。